Year All2024202320222021 Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024 05-01-2024 Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024 04-29-2024 Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting 04-15-2024 Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility 04-10-2024 Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates 03-28-2024 Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia 03-26-2024 Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference 03-25-2024 Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024 03-18-2024 Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C 03-04-2024 Zevra Therapeutics to Participate at Upcoming Investor Conferences 02-28-2024
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024 04-29-2024
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting 04-15-2024
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility 04-10-2024
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates 03-28-2024
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia 03-26-2024
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024 03-18-2024
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C 03-04-2024